<i>In vitro</i> and <i>in silico</i> hybrid approach to unveil triterpenoids from <i>Helicteres hirsuta</i> leaves as potential compounds for inhibiting Nrf2.

ABSTRACT: Cancer is a leading global health concern, with over 20 million new cases and 9.7 million deaths reported in 2022. Chemotherapy remains a widely used treatment, but drug resistance, which affects up to 90% of treatment outcomes, significantly hampers its effectiveness. The transcription factor Nrf2, which is crucial for cellular defense against oxidative stress, plays a dual role in cancer treatment. Although Nrf2 activation can suppress early carcinogenesis, its overexpression in cancer cells contributes to drug resistance, resulting in poor patient outcomes. Thus, inhibiting Nrf2 has emerged as a promising strategy for overcoming cancer drug resistance. Natural compounds such as luteolin and brusatol have shown potential in inhibiting Nrf2, although with limitations. This study isolates

SUBMITTER: Nguyen MH 

PROVIDER: S-EPMC11749225 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature